MRP4/ABCC4 Antibody [D3L18] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat

Usage Information

Dilution
WB1:1000 IP1:50 IHC1:200

Application
WB, IP, IHC

Reactivity
Human, Mouse, Rat

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
140-200 kDa

Positive Control	Human non-small cell lung carcinoma; Human prostate carcinoma; SW620 cells; LNCaP cells; HT-29 cells
Negative Control	U-2 OS cells

Datasheet & SDS

Biological Description

Specificity
MRP4/ABCC4 Antibody [D3L18] detects endogenous levels of total MRP4/ABCC4 protein.

Clone
D3L18

Synonym(s)
ATP-binding cassette sub-family C member 4; MRP/cMOAT-related ABC transporter; Multi-specific organic anion transporter B; MOAT-B; Multidrug resistance-associated protein 4; ABCC4; MOATB; MRP4

Background
MRP4 (ABCC4/Multidrug Resistance Protein 4), a member of the ATP-binding cassette (ABC) transporter MRP subfamily, functions as an ATP-dependent efflux pump that exports a wide range of organic anions across plasma and intracellular membranes, critically regulating intracellular levels of signaling nucleotides such as cAMP and cGMP, nucleoside analogs, prostaglandins, and chemotherapeutic drugs. MRP4 exhibits the canonical ABC transporter topology with two transmembrane domains (TMD1 and TMD2) forming substrate-binding pockets, two nucleotide-binding domains (NBDs) for ATP hydrolysis, and an extracellular lasso loop unique to MRPs that modulates transport directionality, adopting inward-facing (substrate binding) to outward-facing (efflux) conformations upon ATP-driven dimerization of the NBDs. MRP4 extrudes cAMP from leukemia cells to maintain low intracellular levels that suppress PKA-mediated differentiation and promote proliferation, whereas in colorectal cancer cells, MRP4 inhibition elevates plasma membrane cAMP pools, activating localized PKA to enhance migration and invasion via cytoskeletal remodeling. MRP4 also exports exogenous prostaglandins into COX-deficient pancreatic tumors, fueling autocrine growth signaling. MRP4 is localized to basolateral kidney tubules, brain astrocytes, and platelets, where it controls nucleotide homeostasis and drug disposition, while pathologically, overexpression confers multidrug resistance in leukemia, neuroblastoma, and renal cell carcinoma by effluxing nucleoside analogs.

Background

MRP4 (ABCC4/Multidrug Resistance Protein 4), a member of the ATP-binding cassette (ABC) transporter MRP subfamily, functions as an ATP-dependent efflux pump that exports a wide range of organic anions across plasma and intracellular membranes, critically regulating intracellular levels of signaling nucleotides such as cAMP and cGMP, nucleoside analogs, prostaglandins, and chemotherapeutic drugs. MRP4 exhibits the canonical ABC transporter topology with two transmembrane domains (TMD1 and TMD2) forming substrate-binding pockets, two nucleotide-binding domains (NBDs) for ATP hydrolysis, and an extracellular lasso loop unique to MRPs that modulates transport directionality, adopting inward-facing (substrate binding) to outward-facing (efflux) conformations upon ATP-driven dimerization of the NBDs. MRP4 extrudes cAMP from leukemia cells to maintain low intracellular levels that suppress PKA-mediated differentiation and promote proliferation, whereas in colorectal cancer cells, MRP4 inhibition elevates plasma membrane cAMP pools, activating localized PKA to enhance migration and invasion via cytoskeletal remodeling. MRP4 also exports exogenous prostaglandins into COX-deficient pancreatic tumors, fueling autocrine growth signaling. MRP4 is localized to basolateral kidney tubules, brain astrocytes, and platelets, where it controls nucleotide homeostasis and drug disposition, while pathologically, overexpression confers multidrug resistance in leukemia, neuroblastoma, and renal cell carcinoma by effluxing nucleoside analogs.

References
https://pubmed.ncbi.nlm.nih.gov/37217525/ https://pubmed.ncbi.nlm.nih.gov/37683641/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%